Gait Assessment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Table 2
Demographic and clinical characteristics of the sample.
Variables
CIDP patients
Age at onset (years) ()
55.9 (13.6)
Sex
Male, (%)
15 (75)
Female, (%)
5 (5)
EFNS/PNS criteria (2021)
CIDP, (%)
19 (95)
Possible CIDP, (%)
1 (5)
Clinical form
Typical CIDP, (%)
9 (45)
Multifocal CIDP, (%)
4 (20)
Distal CIDP, (%)
6 (30)
Sensory predominant CIDP, (%)
1 (5)
Disease duration (years) (mean/IQR)
3.6 (6.7)
Response to first-line treatment
14/20 (70%)
IVIg
12/16 (75%)
Corticosteroids
2/4 (50%)
Response to second-line treatment
3/5 (60%)
IVIg
1/1 (100%)
Corticosteroids
2/4 (50%)
Baseline scales of CIDP
INCAT total (mean/IQR)
3 (3)
IRODS centile ()
54.4 (16.3)
MRC-SS (mean/IQR)
57 (5)
Grip strength (kPa)—right hand ()
51.5 (28.1)
TUG (sec) (mean/IQR)
11 (12)
10MWT (sec) (mean/IQR)
10 (11.5)
30SCS (rep) (mean/IQR)
5 (11)
IVIg: intravenous immunoglobulins; INCAT: Inflammatory Neuropathy Cause and Treatment; I-RODS: Inflammatory Rasch-Built Overall Disability Scale; MRC-SS: manual muscle strength according to the Medical Research Council sum score; TUG: Timed Up and Go; 10MWT: 10-Meter Walk Test; 30SCS: 30-Second Chair Stand; sec: seconds; rep: repetitions.
